Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Currently the main and most reliable methods of pre-screening and early diagnosis of Alzheimer’s disease (AD) are lumbar punctures and amyloid positron emission tomography (PET) imaging. A lumbar puncture is used to take a sample of cerebrospinal fluid (CSF) from patients in order to measure levels of amyloid-β and tau, however this is a very invasive procedure. Amyloid PET imaging on the other hand is very expensive and therefore difficult to widely implement in clinical practice. Milica Kramberger, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia, explains the value of blood-based biomarkers, such as plasma phosphorylated-tau181 (p-tau181), in providing a less invasive and cheaper diagnostic and screening tool for AD. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.